dr peter attia semaglutide 246 - AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent GLP-1 agonists and the willpower

Metabolic changes in tamoxifen-resistant MCF7 breast cancer cells

Cardiovascular safety DPP-4 inhibitors provide no benefits above the standard of care for people with established or high risk of atherosclerotic cardiovascular disease, heart failure or chronic kidney disease

This weight-loss pill is attracting new patients, with roughly 80% of prescriptions issued to those who had never taken GLP-1s before, according to management

Shima Hadidchi MD Family Practice, we understand the importance of having access to affordable treatments and superior patient care

European journal of obstetrics, gynecology, and reproductive biology